Date: 2013-02-20
Type of information: Licensing agreement
Compound: GlymaxX® Antibody Glyco-Engineering technology
Company: ProBioGen (Germany) undisclosed global pharma company
Therapeutic area:
Type agreement: licensing
Action mechanism: The GlymaxX® technology is based on the stable expression of a heterologous enzyme in the antibody producing cells. GlymaxX® prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the introduction of a gene for an enzyme which deflects the producer cells’ pathway of fucose biosynthesis. GlymaxX® is universally applicable to different CHO hosts and other eukaryotic cell species, and it is simple and potent. GlymaxX® can be rapidly applied in a few weeks to any existing antibody producer cell line, or can be introduced into entire animal cell expression platforms by modifying host cell lines.
Disease:
Details: * On February 20, 2013, Probiogen has announced that another global pharma company has licensed its GlymaxX® ADCC-enhancement technology. The license with an option for a commercial license covers the modification of the company’s antibody production platform and the generation of multiple antibodies with enhanced ADCC (Antibody-dependent cellular cytotoxicity assays) potency.
Financial terms: Financial details are not disclosed.
Latest news:
